Melanoma differentiation-associated gene 5 (MDA5) dermatomyositis, characterized by antibodies targeting MDA5, has recently emerged as a distinct subset of the idiopathic inflammatory myopathies. It is identified by distinctive clinical manifestations, including fever, characteristic skin lesions, nonerosive symmetrical polyarthritis, and rapidly progressive interstitial lung disease (ILD); often there is minimal to no muscle involvement. Classifying the disease into rapidly progressive ILD, rheumatic, and vasculopathic subtypes, as reported in some studies, may help predict prognosis. Prompt recognition of its unique clinical manifestations and initiation of aggressive immunosuppressive therapy are vital to improve outcomes in this potentially life-threatening condition.
Soumya Chatterjee (2025) studied this question.